56results about How to "Diagnosis helps" patented technology

The invention relates to detection of genotypes, in particular to a primer and a probe for detecting relative fusion genes of leukemia and a kit of the primer and the probe. The kit can qualitatively detect quantity of BCR-ABL, AML1-ETO and PML-RARa of the relative fusion genes of the leukemia in human marrow specimens so as to instruct clinical diagnosis and pharmacy of the leukemia.

Provided is a distribution transformer integrated detection device comprising: a mobile device, and a detection module, an integrated wiring module, an integrated controller and a central controller arranged on the mobile device, the detection module accesses the integrated controller through the integrated wiring module to realize the automatic test of a distribution transformer, and the central controller realizes the analysis and storage of the test data. The distribution transformer integrated detection device can be conveniently detached and assembled and can be conveniently checked and maintained, performs integral control and management to complete the overall test report, performs the unified data management and diagnosis analysis, can comprehensively improve the efficiency, level, and quality of the electrical test, reduces the heavy carrying workload of the equipment during the test, improves the reliability of the transformer operation and technical management level to a large extent, can safely, flexibly, rapidly and effectively complete the relevant test projects, and realizes the intensive, digitalized, intelligent, and maneuvering transformation of the transformer equipment on-site test.

The invention provides a biomarker for diagnosing white matter lesion and application of the biomarker. The biomarker is ceramide (m18: 1 (4E) / 24: 1 (15Z)) (Cer (m18: 1 (4E) / 24: 1 (15Z))). According to the present invention, the biological marker ceramide (m18: 1 (4E) / 24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavin A), cucurbitacine E (Cucurbitacine E), cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) or ceramide (d18: 0 / 24: 1 (15Z)) (Cer (d18: 0 / 24: 1 (15Z))) so as to determine whether the white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

The invention belongs to disease detection kit, and concretely relates to a kit for auxiliary diagnosis of Kawasaki disease by using miRNA as a biological label. The nucleic acid label is hsa-miR-223-3p, and the kit includes a primer subjected to a real-time quantitative polymerase chain reaction (RT-qPCR) for hsa-miR-223-3p. The kit can combine blood routine examination, high-sensitivity C reactive protein, erythrocyte sedimentation rate and cardiac ultrasonography, and is conducive to auxiliary diagnosis of Kawasaki disease and prediction damage of coronary artery.

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is ceramide (d18: 0 / 24: 1 (15Z)) (Cer (d18: 0 / 24: 1 (15Z))). According to the present invention, the biomarker ceramide (d18: 0 / 24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavanin A), cucurbitacine E (Cucurbitacine E) or cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) so as to determine whether the white matter lesion exists or not; the biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is cholesterol-alpha-D-glucoside. The biomarker cholesterol-alpha-D-glucoside is combined with 6Z,9Z,20-eicosatrienoic acid, ceramide (m18:1(4E) / 24:1(15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22:6 or ceramide (d18:0 / 24:1(15Z)) to judge whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

The invention relates to an overheating fault diagnosis method of a transformer. The method comprises steps of calculating basic probability distribution functions of all kinds of faults on the evidence of codeless four ratios and characteristic gas by use of a posterior probability SVM; and then according to evidence theory definition, calculating fusion results of all kinds of the results under combined effects of multi-evidence bodies for belief functions of different evidence bodies. A probability estimation module is introduced in a 'one versus one' multiclass SVM by use of a pair-wise coupling algorithm, so defects of limitations on following data processing imposed by hard decision output when a traditional SVM is solving multiclass problems are overcome and an SVM probability output problem is effectively solved. According to the invention, by fully using redundant and complementation information of chromatographic data and electric test data and applying the D-S evidence theory, correction and reliability of comprehensive diagnosis results based on multi-default characteristics are greatly improved than the diagnosis based on single-default characteristics, which facilitates diagnosis of fault types of the transformer and has practical significance for formulation of maintenance strategies of the transformer.

The invention discloses a plasma exosome tRFs marker and an application thereof to breast cancer diagnosis. The marker is an exosome-derived tRF-Ser-AGA-018. The application of the marker includes theoperating steps: A building a unified specimen bank and a database, acquiring blood samples and tissue samples conforming to standards by standard operating procedures, and systematically collectingcomplete clinical data of included crowds; B analyzing tumor-induced exosome-derived tRFs disparity expression spectra in blood, selecting plasma samples of breast cancer cases and healthy persons, breast cancer tissues and para-carcinoma tissues, extracting exosomes, sequencing tRFs and tiRNA and screening out differentially expressed tRFs; C performing QRT-PCR (quantitative reverse transcriptionpolymerase chain reaction) analysis on the screened differentially expressed tRFs in large sample crowds. The tumor-induced exosome tRFs in the blood is a novel biomarker which realizes stability, minimal invasiveness and real-time monitoring, the sensitivity and the specificity of disease diagnosis are greatly improved, and successful development of the non-coding RNA (ribonucleic acid) biomarker is beneficial to breast cancer diagnosis.

The invention relates to a method for capturing the phthisic Proteome in biological samples by supporting the stroma with the bead and separating the bead from the samples by the magnetic separator without the centrifuged samples. Then conduct the protein fingerprinting by the analysis of mass spectrography. The reagent kit tests the sensibility and the specificity of the normal person with the tuberculosis by Double Blind Test, which are all 100percent, among which the deviant SAA A can be used as blood serum in vitro for testing the normal person, minor tuberculosis patient, recrudescent tuberculosis patient, severe tuberculosis patient and tuberculosis patient after effective treatment. The elevated deviant SAA A shows poor treatment effectiveness, severe tuberculosis and the recrudescent tuberculosis, thus being a protein fingerprinting group for early warning of the early detection on tuberculosis worsening and prediction on tuberculosis recrudescence. The method provided in the invention can be used as the reagent kit to distinguish the protein fingerprinting or mass spectrum mapping between the normal person and the tuberculosis patient. The method is correct, convenient and fast.

The invention relates to a proteome acquiring method which utilizes the method of the bead supporting stroma to capture the liver cancer protein group in the biology samples, and utilizes the magnetic separator to separate the bead and the sample without eccentric samples, and then utilizes the matter hidden method to analyze. The invention can be used in the protein fingerprint of the normal people and the liver cancer or the reagent box of the mass spectrum polypeptide atlas. The invention is accurate, convenient and quick.

The invention provides a specific autoantibody of the PBC and a corresponding antigen. RBE (relative biological effectiveness) TP (total protein) of cholangiocarcinoma cells is taken as the antigen of the specific autoantibody; an IB (immunoblotting) method is adopted to detect the serum of a PBC patient; an autoantibody aiming at protein with the molecular weight about 20kD is detected and named Sp20 antibody; and then the Sp20 antibody is separated and obtained from the serum of the PBC patient through two-dimensional electrophoresis. The invention further provides an application of the Sp20 antibody in preparation of a kit for PBC diagnosis. By means of research on the mechanism of the Sp20 antibody in PBC incidence, theoretical basis is provided for early diagnosis, early treatment and prognostic judgment of PBC patients, diagnosis for AMA (anti mitochondrial antibody)-negative PBC patients is facilitated, and differential diagnosis with other autoimmune diseases is facilitated.

The invention relates to a medical image processing method, a medical image processing device, a storage medium and computer equipment. According to the invention, during processing of a medical image, when it is detected that a first-level image structure contains abnormal signs, abnormal sign detection is continuously conducted on the second-level image structure contained in the first-level image structure, that is, abnormal sign detection is conducted on all the image structures according to the sequence from the high level to the low level, so that the abnormal detection can be comprehensive; and the target image structure containing the abnormal signs is determined based on the detection result, and then abnormal classification is performed through at least one classification model,so that the accuracy of the abnormal classification result can be enhanced, reliable abnormal category information can be obtained to support the doctor to perform further diagnosis, and the doctor can perform accurate diagnosis in the later period.

The invention relates to an FN test paper for quickly diagnosing bladder cancer, which comprises a substrate, a sample pad, a gold colloidal pad, a nitrocellulose membrane layer and an absorbent paper layer, wherein the substrate is sequentially covered by the sample pad, the gold colloidal pad, the nitrocellulose membrane layer and the absorbent paper layer, and the gold colloidal pad comprises a gold-labelled antibody compound combining colloidal gold and anti-urine fibronectin antibodies. The invention also discloses application of the FN test paper for quickly diagnosing the bladder cancer. The FN test paper for quickly diagnosing the bladder cancer has the advantages of high speed, high sensitivity, strong specificity, good stability, simple and convenient operation, no need of any instrument or equipment, visual and reliable result judgment, easy grasp and suitability for diagnosis of the disease of bladder cancer and self-monitoring of the condition of the disease by detection of the urine fibronectin in urine.

This invention relates to a protein dactylography for analysis of biological sample. This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This method can be used to the diagnosis of cell and clinic diseases, such as tumor with accuracy, convenience and quickness.

The invention provides a biomarker for diagnosing cerebral infarction and white matter lesion and application of the biomarker. The biomarker is an application of galactosylceramide in preparation of a detection reagent for diagnosing cerebral infarction and white matter lesions, and the biomarker galactosylceramide is combined with glucosylceramide, beta-allopietapentaol, platyclalene, 1, 3Z, 6Z, 9Z-nonane tetraene, p-cymene, oxalic acid, 3-(stearoyloxy)-4-(trimethyl ammonium) butyrate for diagnosing cerebral infarction and white matter lesions, so the risk of suffering from cerebral infarction and white matter lesion can be judged, and the cerebral infarction and white matter lesion can be prevented in advance.

This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method is used to detect the protein fingerprint in the normal cell, restocarcinoma patient cell and rectal polyp patient cell.

The invention relates to in-vitro detection reagents for clinical diagnosis and in particular relates to a cancer urine detection reagent. The urine detection reagent is prepared from iodine, potassium iodide, mercury chloride, concentrated sulfuric acid and distilled water. After the test solution is dripped into the urine, the urine immediately develops color, precipitates of different colors are naturally downwards precipitated within 5-15 minutes, whether the detected patients are healthy patients or patients suffering from nephritis, benign tumors and malignant tumors can be judged by virtue of different colors developed by the solution and precipitates. According to the detection reagent disclosed by the invention, the defects in the prior art are overcome, and the detection reagent is a rapid metabolic disorder urine test reagent of a novel formula and has high stability, sensitivity and specificity and wide application range.

This invention relates to a protein fingerprinting using stranded chromatography catch and analysis proteins. The method identifies and detects proteins in mass spectrometry. Analysis of the data is obtained in the form of computer-readable bar code format (protein fingerprint). The invention method can be used to detect blood cells in patients with renal cell carcinoma and normal cell protein fingerprints. The method is accurate, fast and convenient.

The invention provides application of a biomarker phosphatidylinositol (22: 0 / 19: 0) in preparation of a detection reagent for diagnosing cerebral infarction of a white matter lesion patient. The risk of cerebral infarction of the white matter lesion patient is judged by combining the biomarker lipophosphatidylinositol (22: 0 / 19: 0) with glucosylceramide (d18: 0 / 24: 1 (15Z)), beta-hydroxyethyl ethanolamine, tomatidine, phosphatidylserine (22: 6 / 20: 1) or decanoyl carnitine. Cerebral infarction can be prevented in advance.

The standard substance kit is a standardization quality-controlled blood serum sampler packaged in tubule. Under -80 deg. C, the pooled serum is taken out and is diluted in U9 buffer solution in 1:2 mixing ratio; saving it at 25 deg. C. A quantification mass spectrographic analysis under the control of standardization quality-controlled O type blood serum is used for test.

This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method can be used to detect protein fingerprint in the normal cell and cancer of stomach patient cell in the blood.

The invention provides biomarkers for diagnosing cerebral infarction and white matter lesions and applications thereof. The biomarker is the application of galactosylceramide in the preparation of detection reagents for diagnosing cerebral infarction and white matter lesions. The biomarkers Galactosylceramide combined with glucosylceramide, β‑alpipentol, arborvitene, 1,3Z,6Z,9Z‑nonanetetraene, p-cymene, oxalic acid, 3‑(stearyloxy) ‑4‑(Trimethylammonium) butyrate can be used to judge the risk of cerebral infarction and white matter lesions, and can prevent and prevent cerebral infarction and white matter lesions in advance.

The invention relates to an albumen dactyloscopy analyzed by protein group. Utilizing mass spectrography to distinguish, the method discovers a new end-cut fiber albumen peptide A which can be used to test lymph node transfer of gastric cancer cells. The method is accurate, convenient and speed.

The invention discloses a transformer fault diagnosis method and system based on a neural network, and the method comprises the steps: taking a transformer fault diagnosis result as a target object, carrying out the coding of the target object, setting an initial cluster, and eliminating and updating a new group; selecting an error function calculated each time as a fitness function, initially calculating a fitness population of each population, selecting a new population and eliminating an old population; genetic operators are selected according to the probability, operator selection, crossover operators and mutation operators are carried out in sequence, and a fault diagnosis result is generated. According to the invention, intelligent diagnosis of the fault type and the fault degree of the transformer can be realized, diagnosis of the fault of the transformer is facilitated, and the method has an effective guiding effect on engineering practice.

The invention relates to detection of genotypes, in particular to a primer and a probe for detecting relative fusion genes of leukemia and a kit of the primer and the probe. The kit can qualitatively detect quantity of BCR-ABL, AML1-ETO and PML-RARa of the relative fusion genes of the leukemia in human marrow specimens so as to instruct clinical diagnosis and pharmacy of the leukemia.

This invention also relates to protein dactylography method for analyzing for the protein group got by retention chromatography. This method adopts mass spectroscopy to distinguish and detect protein group. The analysis data takes the form of bar code (protein dactylography) read by computer. This invention method can be used to detect protein fingerprint in the normal cell and cancer of stomach patient cell in the blood.

The invention discloses a protein biological marker for diagnosing osteoporosis and its application, and belongs to the technical field of biological detection. The present invention uses Abl Interactor 1 protein as a biomarker for osteoporosis diagnosis. The protein biomarkers provided by the present invention can be used to prepare diagnostic kits, and have excellent diagnostic value when applied to blood samples to diagnose osteoporosis. Using the protein of the present invention alone, the diagnostic AUC can reach 0.76. Taking 0.376ng / ml as the cut-off point, the sensitivity and specificity were 73.3% and 64.3%, respectively. Combined with CTX and P1NP, the diagnostic AUC can reach 0.78. The protein can be used as a biomarker for the diagnosis of human osteoporosis blood samples, which is helpful for the diagnosis of osteoporosis, the identification of high-risk groups of osteoporotic fractures, and the prevention and treatment.

The invention discloses a protein fingerprint method for analyzing the protein group. It uses mass spectrography to detect the protein group, and the usable data analyzed by statistics is the bar cod (protein fingerprint) red by the computer. Said bar code can be transformed into one strengthen protein fingerprint drawing instructed by standard mass control serum; the protein can be kept by bar code (digital code) or drawing (strength protein fingerprint drawing) forever after being detected. The invention can be used to detect the protein fingerprint of normal cell and sufferer cell, with high speed and simple process.

The invention provides the application of the biomarker phosphatidylinositol (22:0 / 19:0) in the preparation of detection reagents for diagnosing cerebral infarction in patients with leukoencephalopathy. The biomarker lipophosphatidylinositol (22:0 / 19:0) in combination with glucosylceramide (d18:0 / 24:1(15Z)), β‑hydroxyethylethanolamine, tomatidine, phosphatidylserine (22:6 / 20:1) or decanoyl carnosine Alkaline can be used to judge the risk of cerebral infarction in patients with leukoencephalopathy, which can be used to prevent and prevent cerebral infarction in advance.

The invention discloses a method for detecting and diagnosing abnormal coal mill efficiency based on SVR, which includes the following steps: firstly collect the normal operation data of the coal mill, divide the training set and the verification set according to the proportion, and collect the abnormal / real-time data as the test set . Identify performance variables as model outputs and corresponding operating variables as model inputs, train the model, and use the validation set to determine control limits. Then input the test set and calculate the deviation of the target variable; if the deviation exceeds the control limit, extract the support vector and compare it with the abnormal working conditions to determine the magnitude and direction of the deviation of the variable, and give the order of the variable contribution. Finally, by integrating all efficiency-related models, the causal variables that cause efficiency anomalies and the propagation paths of efficiency anomalies can be determined. By using the method of the invention, the abnormal condition of the efficiency of the coal mill can be detected, and the mining of abnormal variables and the diagnosis of abnormal causes can be realized.